iwCLL 2023 | Monitoring infection risk in patients with CLL & insights into the PreVent-ACaLL trial
Carsten Niemann
• 6 Oct 2023
Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, discusses the importance of monitoring the risk of infections in patients with chronic lymphocytic leukemia (CLL) following treatment with targeted therapies and chemoimmunotherapy. Dr Niemann also shares insights into the PreVent-ACaLL trial (NCT03868722), which makes use of machine learning to identify patients at risk of infection following therapy. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
